The cell and gene therapy (CGT) industry is growing rapidly, due to their potential to target chronic and rare diseases that previously had limited treatment options. Yet, there are many challenges to developing these innovative new therapies that cannot be addressed using traditional manufacturing models and processes.
Sign up to download Effectively Securing Cell And Gene Therapies With Closed Systems White Paper
